Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals is a global biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. The company has pioneered a new class of complement medicine, targeting C3, the central protein in the complement cascade. Apellis has successfully transitioned to a commercial-stage company with two FDA-approved products: SYFOVRE (pegcetacoplan injection) for geographic atrophy (GA) and EMPAVELI (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH) and certain rare kidney diseases (C3G and primary IC-MPGN). The company continues to invest in its pipeline, exploring additional indications for its complement-targeting platform.